Mebeverine and Pregnancy
Mebeverine lacks adequate safety data for use during pregnancy and should be avoided unless absolutely necessary, as there are no human studies establishing its safety profile in pregnant women.
Critical Evidence Gap
The provided FDA drug label information 1 is incorrectly labeled - it describes metoprolol (a beta-blocker), not mebeverine. This represents a significant documentation error, as no actual FDA-approved mebeverine drug label data is available in the evidence provided.
Available Evidence Assessment
Guideline Evidence
The major IBD pregnancy guidelines 2, 3 do not mention mebeverine at all. These comprehensive 2024 and 2016 guidelines discuss multiple medications safe for use in pregnancy (mesalamine, sulfasalazine, azathioprine, anti-TNF biologics) but notably exclude mebeverine from their recommendations, suggesting it is not considered a standard or well-studied option during pregnancy.
Research Evidence Limitations
All research studies provided 4, 5, 6, 7, 8, 9, 10 focus exclusively on:
- Efficacy in IBS treatment
- Mechanism of action studies
- Comparison with placebo
- Novel derivative development
None of these studies address pregnancy safety, teratogenicity, or fetal outcomes.
Clinical Recommendation
Avoid mebeverine during pregnancy due to:
- Absence of human pregnancy data - No studies evaluating congenital malformations, pregnancy outcomes, or fetal exposure
- Lack of guideline support - Not mentioned in authoritative GI pregnancy guidelines that extensively cover medication safety
- Unknown placental transfer - No data on whether mebeverine crosses the placenta
- Unknown pregnancy category - No FDA pregnancy classification available
Alternative Approaches for GI Symptoms in Pregnancy
If treating IBS-like symptoms during pregnancy, consider evidence-based alternatives mentioned in guidelines 11:
- For nausea/vomiting: Vitamin B6, H1 antihistamines, ginger
- For constipation: Osmotic laxatives, fiber preparations, probiotics
- For GERD: Calcium carbonate, H2 antihistamines (famotidine has pregnancy data 12), proton pump inhibitors
If Mebeverine Use Is Considered Essential
Only in rare circumstances where benefit clearly outweighs unknown risks:
- Document thorough risk-benefit discussion with patient
- Use lowest effective dose
- Avoid first trimester if possible (organogenesis period)
- Arrange enhanced fetal monitoring
- Consider consultation with maternal-fetal medicine
Key Pitfall
Do not assume mebeverine is safe simply because it is an antispasmodic - absence of evidence is not evidence of safety, particularly when comprehensive pregnancy guidelines omit the medication entirely while including multiple other GI drugs.